Health ❯ Obesity

Weight Loss

Medications Pharmaceuticals Pharmaceutical Treatments Medication Bariatric Surgery Surgery Clinical Trials GLP-1 Drugs Weight Loss Drugs Dietary Interventions Injections Pharmacology Interventions Medical Treatments Treatment Strategies Clinical Studies Fitness Programs Semaglutide Treatment Options Treatment Methods GLP-1 Hormone Obesity Drugs Dietary Phases Brain Activity Brain-Gut Microbiome Interplay Intermittent Energy Restriction Metagenomics Physiological Parameters Obesity-related Comorbidities Appetite-Suppressants Drug Comparison Effects of Tirzepatide Exercise Impact Drug Trials Weight Loss Medications Weight Loss Journey Medication Efficacy Appetite Suppressants Dietary Supplements Side Effects Comorbidities Gastric Bypass Alternatives Anti-obesity Drugs Factors Influencing Weight Loss Pharmaceutical Drugs Psychological Effects Off-label Drug Use Pharmaceutical Alternatives Dietary Education Men's Health Medication Adherence Weight Maintenance Wegovy Fitness Journey Weight Management Weight Loss Surgery Mental Health Drug Development Weight Loss Treatments Pharmaceutical Innovations Medicines Fitness GLP-1 Medications Physical Health Personal Struggles Appetite Regulation Mental Challenges Biological Responses Research Patient Care Dietary Changes Weight Loss Camps Health Complications Diet Quality Improvement Text Messages Research Trials Behavioral Economics Research Studies Caloric Restriction Prescription Medications Mounjaro Rybelsus, Danuglipron, Orforglipron Drug Treatments Medical Devices Gastric Balloons Artificial Sweeteners Personal Transformation Lifestyle Changes Diet Companies Diet, Exercise Body Weight Reduction Calorie-Deficit Diet Misperceptions about Disease Management

Oprah Winfrey Recasts Obesity as Disease in New Book, Backs GLP-1s as Long-Term Care

She presents GLP-1 drugs as ongoing treatment for a chronic condition, citing weight regain after a year off.

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds

Pilot Study Ties GLP-1 Drugs to Slower Alcohol Absorption and Milder Intoxication

BMJ Retracts Apple Cider Vinegar Weight-Loss Study After Errors and Data Irregularities

Monthly Phone Coaching Sustains Weight Loss for 20 Months as Algorithmic Extra Calls Fall Short

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Healthy Diet Cuts Chronic Pain Beyond Weight Loss, UniSA Trial Finds

Edible Microbeads That Trap Dietary Fat Enter First Human Trial After Rat Weight-Loss Results

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

Key Treatment and Patient Traits Predict Weight Loss Success With GLP-1 Agonists